Craft
UCB

UCB

Patients Reached

3.5 M

FY, 2020

Revenue

€5.5 B

FY, 2021

Market Capitalization

€14.5 B

2023-01-23

UCB Summary

Company summary

Overview
UCB is a biopharma company, focusing on neurology and immunology. It develops products for the treatment of epilepsy, Parkinson's disease, restless legs syndrome, ankylosing spondylitis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis.
Type
Public
Status
Active
Founded
1928
HQ
Anderlecht, BE | view all locations
Website
http://www.ucb.com/
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key people

  • Jean-Christophe Tellier

    Jean-Christophe Tellier, Chief Executive Officer & Chairman of the Executive Committee

  • Kirsten Lund-Jurgensen

    Kirsten Lund-Jurgensen, Executive Vice President of Supply & Technology Solutions

    • Dhavalkumar Patel

      Dhavalkumar Patel, Executive Vice President & Chief Scientific Officer

      • Emmanuel Caeymaex

        Emmanuel Caeymaex, Executive Vice President of Immunology Solutions & Head of US

      Operating MetricsView all

      Patients Reached

      3.5M

      FY, 2020

      Projects in Pipeline

      12
      71.4%

      FY, 2020

      Locations (Research and Development)

      12

      FY, 2019

      LocationsView all

      40 locations detected

      • Anderlecht, Bruxelles HQ

        Belgium

        60 Allée de la Recherche

      • Raleigh, NC

        United States

        8010 Arco Corporate Dr

      • Smyrna, GA

        United States

        1950 Lake Park Dr SE

      • Malvern, VIC

        Australia

        Level 1/1155 Malvern Rd

      • Wien, Wien

        Austria

        Twin Tower Wienerbergstrasse 11/12a

      • Braine-l'Alleud, Wallonie

        Belgium

        Chemin du Foriest

      and 34 others

      UCB Financials

      Summary financials

      Revenue (H1, 2022)
      €2.7B
      Gross profit (H1, 2022)
      €2.5B
      Net income (H1, 2022)
      €399.0M
      Cash (H1, 2022)
      €515.0M
      EBIT (H1, 2022)
      €490.0M
      Enterprise value
      $17.0B

      Footer menu